Effect of megestrol acetate on the human pituitary-adrenal axis

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

A few previous reports have suggested that megestrol acetate, a synthetic progestational agent frequently used as an antineoplastic drug, suppresses serum cortisol concentrations in humans. To explore this concept further, we prospectively performed several measurements of the pituitary-adrenal axis in patients receiving megestrol acetate (160 or 800 mg/day). The data from these evaluations demonstrate that megestrol acetate reversibly decreases serum cortisol concentrations in humans and that this effect seems to originate from a suppression of the pituitary-adrenal axis. Additional studies should be conducted to determine the implications of the low levels of serum cortisol.

Original languageEnglish (US)
Pages (from-to)1160-1162
Number of pages3
JournalMayo Clinic Proceedings
Volume67
Issue number12
StatePublished - 1992

Fingerprint

Megestrol Acetate
Hydrocortisone
Serum
Progestins
Antineoplastic Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of megestrol acetate on the human pituitary-adrenal axis. / Loprinzi, Charles Lawrence; Jensen, Michael Dennis; Jiang, N. S.; Schaid, Daniel J.

In: Mayo Clinic Proceedings, Vol. 67, No. 12, 1992, p. 1160-1162.

Research output: Contribution to journalArticle

@article{0e22ff09335747688651a6952f79bc63,
title = "Effect of megestrol acetate on the human pituitary-adrenal axis",
abstract = "A few previous reports have suggested that megestrol acetate, a synthetic progestational agent frequently used as an antineoplastic drug, suppresses serum cortisol concentrations in humans. To explore this concept further, we prospectively performed several measurements of the pituitary-adrenal axis in patients receiving megestrol acetate (160 or 800 mg/day). The data from these evaluations demonstrate that megestrol acetate reversibly decreases serum cortisol concentrations in humans and that this effect seems to originate from a suppression of the pituitary-adrenal axis. Additional studies should be conducted to determine the implications of the low levels of serum cortisol.",
author = "Loprinzi, {Charles Lawrence} and Jensen, {Michael Dennis} and Jiang, {N. S.} and Schaid, {Daniel J}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "1160--1162",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Effect of megestrol acetate on the human pituitary-adrenal axis

AU - Loprinzi, Charles Lawrence

AU - Jensen, Michael Dennis

AU - Jiang, N. S.

AU - Schaid, Daniel J

PY - 1992

Y1 - 1992

N2 - A few previous reports have suggested that megestrol acetate, a synthetic progestational agent frequently used as an antineoplastic drug, suppresses serum cortisol concentrations in humans. To explore this concept further, we prospectively performed several measurements of the pituitary-adrenal axis in patients receiving megestrol acetate (160 or 800 mg/day). The data from these evaluations demonstrate that megestrol acetate reversibly decreases serum cortisol concentrations in humans and that this effect seems to originate from a suppression of the pituitary-adrenal axis. Additional studies should be conducted to determine the implications of the low levels of serum cortisol.

AB - A few previous reports have suggested that megestrol acetate, a synthetic progestational agent frequently used as an antineoplastic drug, suppresses serum cortisol concentrations in humans. To explore this concept further, we prospectively performed several measurements of the pituitary-adrenal axis in patients receiving megestrol acetate (160 or 800 mg/day). The data from these evaluations demonstrate that megestrol acetate reversibly decreases serum cortisol concentrations in humans and that this effect seems to originate from a suppression of the pituitary-adrenal axis. Additional studies should be conducted to determine the implications of the low levels of serum cortisol.

UR - http://www.scopus.com/inward/record.url?scp=0026488713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026488713&partnerID=8YFLogxK

M3 - Article

C2 - 1469926

AN - SCOPUS:0026488713

VL - 67

SP - 1160

EP - 1162

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -